$NDRA News

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $25

ENDRA Life Sciences Q1 EPS $(1.09) Beats $(1.14) Estimate

ENDRA Life Sciences Reports Multi-Site Validation And MRI-Level Accuracy Of TAEUS Liver Device

ENDRA Life Sciences Q4 EPS $(3.25) Misses $(1.95) Estimate

ENDRA Life Sciences Says On March 19 , Reduced Number Of Employees In Order To Reduce Cash Expenditures And Extend Its Operational Runway; Expects To Incur Pre-Tax Cash Charges Of ~$51,000 Associated With Severance Payments To Former Employees

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

ENDRA Life Sciences Initiates Review Of Strategic Alternatives

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

ENDRA Life Sciences Announces Results From Study Evaluating TAEUS Live Device

Ascendiant Capital Maintains Buy on ENDRA Life Sciences, Lowers Price Target to $30

ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

ENDRA Life Sciences Announces New Results From 2025 TAEUS Liver Device Feasibility Study Showing TAEUS' TAFF Measurement Closely Tracks MRI-PDFF Gold Standard At Critical LFF Thresholds Of 12-17% And 20-22%

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

ENDRA's Updated TAEUS Liver Device Shows MRI-Level Accuracy Across All Stages Of Steatotic Liver Disease In New Feasibility Study

ENDRA Life Sciences Announces Prelim. Results From Single-Site Clinical Feasibility Study Evaluating TAEUS Liver Device For Quantifying Liver Fat Fraction

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

ENDRA Life Sciences Q3 EPS $(2.10) Misses $(1.95) Estimate

Endra Life Sciences commences staking of HYPE digital asset holdings

ENDRA Life Sciences Begins Staking Of HYPE Digital Asset Holding